p53 alterations in myeloid leukemia

Acta Haematologica

Volumn 111, Issue 1-2, 2004, Pages 100-106

  Boyapati, Anita ^a   Kanbe, Eiki ^a   Zhang, Dong Er ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Acute myeloid leukemia; Chronic myeloid leukemia; Myelodysplastic syndrome; p53

Indexed keywords

PROTEIN P53;

ACUTE GRANULOCYTIC LEUKEMIA; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CORRELATION ANALYSIS; FUSION GENE; GENE ACTIVITY; GENE CONTROL; GENE FUNCTION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; MUTATION RATE; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ACUTE DISEASE; HUMANS; LEUKEMIA, MYELOID; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0345059963     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074489     Document Type: Review

References (65)

1. Asher G, Lotem J, Kama R, Sachs L, Shaul Y: Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. Proc Natl Acad Sci USA 2002;99:13125-13130.
2. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K: Recruitment of p300/CBP in p53-dependent signal pathways. Cell 1997;89:1175-1184.
3. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, Ziv Y: Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998;281:1674-1677.
4. Banker DE, Radich J, Becker A, Kerkof K, Norwood T, Willman C, Appelbaum FR: The t(8;21) translocation is not consistently associated with high Bcl-2 expression in de novo acute myeloid leukemias of adults. Clin Cancer Res 1998;4:3051-3062.
5. Beitel LK, Elhaji YA, Lumbroso R, Wing SS, Panet-Raymond V, Gottlieb B, Pinsky L, Trifiro MA: Cloning and characterization of an androgen receptor N-terminal-interacting protein with ubiquitin-protein ligase activity. J Mol Endocrinol 2002;29:41-60.
6. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD: Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998;281:1677-1679.
7. Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD: Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci USA 1999;96: 13777-13782.
8. Christiansen DH, Andersen MK, Pedersen-Bjergaard J: Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 2001;19:1405-1413.
9. De Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, Spurr NK, Heisterkamp N, Groffen J, Stephenson JR: A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982;300:765-767.
10. Dimartino JF, Cleary ML: Mll rearrangements in haematological malignancies: Lessons from clinical and biological studies. Br J Haematol 1999;106:614-626.
11. Downing JR: The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: Biology and clinical significance. Br J Haematol 1999; 106:296-308.
12. El Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-825.
13. Felix CA: Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1998;1400:233-255.
14. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, Jacks T: p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002;416: 560-564.
15. Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R, Whale AD, Martinez-Diaz H, Rozengurt N, Cardiff RD, Liu X, Wu H: PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 2003;3:117-130.
16. Fuchs SY, Adler V, Buschmann T, Wu X, Ronai Z: MDM2 association with p53 targets its ubiquitination. Oncogene 1998;17:2543-2547.
17. Goetz AW, van der Kuip H, Maya R, Oren M, Aulitzky WE: Requirement for MDM2 in the survival effects of BCR-ABL and interleukin-3 in hematopoietic cells. Cancer Res 2001;61: 7635-7641.
18. Grossman SR, Deato ME, Brignone C, Chan HM, Kung AL, Tagami H, Nakatani Y, Livingston DM: Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 2003;300:342-344.
19. Gu W, Roeder RG: Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997;90:595-606.
20. Hartmann-Petersen R, Seeger M, Gordon C: Transferring substrates to the 26S proteasome. Trends Biochem Sci 2003;28:26-31.
21. Haupt Y, Maya R, Kazaz A, Oren M: MDM2 promotes the rapid degradation of p53. Nature 1997;387:296-299.
22. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B: 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997;1:3-11.
23. Hofmann WK, Takeuchi S, Xiw D, Miller CW, Hoelzer D, Koeffler HP: Frequent loss of heterozygosity in the region of D1S450 at 1p36.2 in myelodysplastic syndromes. Leuk Res 2001; 25:855-858.
24. Honda H, Oda H, Suzuki T, Takahashi T, Witte ON, Ozawa K, Ishikawa T, Yazaki Y, Hirai H: Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: A novel transgenic model for human Ph1-positive leukemias. Blood 1998;91:2067-2075.
25. Honda H, Ushijima T, Wakazono K, Oda H, Tanaka Y, Aizawa S, Ishikawa T, Yazaki Y, Hirai H: Acquired loss of p53 induces blastic transformation in p210 (bcr/abl)-expressing hematopoietic cells: A transgenic study for blast crisis of human CML. Blood 2000;95:1144-1150.
26. Horiike S, Misawa S, Kaneko H, Sasai Y, Kobayashi M, Fujii H, Tanaka S, Yagita M, Abe T, Kashima K, Taniwaki M: Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of Nos 5 and/or 7 and its possible relationship to replication error phenotype. Leukemia 1999;13:1235-1242.
27. Kawano S, Miller CW, Gombart AF, Bartram CR, Matsuo Y, Asou H, Sakashita A, Said J, Tatsumi E, Koeffler HP: Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood 1999;94:1113-1120.
28. Koken MH, Puvion-Dutilleul F, Guillemin MC, Viron A, Linares-Cruz G, Stuurman N, de Jong L, Szostecki C, Calvo F, Chomienne C et al: The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J 1994;13:1073-1083.
29. Krug U, Ganser A, Koeffler HP: Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 2002;21:3475-3495.
30. Kubbutat MH, Jones SN, Vousden KH: Regulation of p53 stability by MDM2. Regulation of p53 stability by MDM2. Nature 1997;387:299-303.
31. Kubbutat MH, Vousden KH: Proteolytic cleavage of human p53 by calpain: A potential regulator of protein stability. Mol Cell Biol 1997;17:460-468.
32. Lai JL, Preudhomme C, Zandecki M, Flactif M, Vanrumbeke M, Lepelley P, Wattel E, Fenaux P: Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia 1995;9:370-381.
33. Lanza C, Gaidano G, Cimino G, Pastore C, Nomdedeu J, Volpe G, Vivenza C, Parvis G, Mazza U, Basso G, Madon E, Lo Coco F, Saglio G: Distribution of TP53 mutations among acute leukemias with MLL rearrangements. Genes Chromosomes Cancer 1996;15:48-53.
34. Laronga C, Yang HY, Neal C, Lee MH: Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J Biol Chem 2000;275:23106-23112.
35. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, Parant JM, Lozano G, Hakem R, Benchimol S: Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003; 112:779-791.
36. Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. Nature 1998; 396:643-649.
37. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM: Binding and modulation of p53 by p300/CBP coactivators. Nature 1997; 387:823-827.
38. Linggi B, Muller-Tidow C, van de Locht L, Hu M, Nip J, Serve H, Berdel WE, van der Reijden B, Quelle DE, Rowley JD, Cleveland J, Jansen JH, Pandolfi PP, Hiebert SW: The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med 2002;8:743-750.
39. Maki K, Mitani K, Yamagata T, Kurokawa M, Kanda Y, Yazaki Y, Hirai H: Transcriptional inhibition of p53 by the MLL/MEN chimeric protein found in myeloid leukemia. Blood 1999;93:3216-3224.
40. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM: p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003;11:577-590.
41. Miller C, Mohandas T, Wolf D, Prokocimer M, Rotter V, Koeffler HP: Human p53 gene localized to short arm of chromosome 17. Nature 1986;319:783-784.
42. Mitani K, Kanda Y, Ogawa S, Tanaka T, Inazawa J, Yazaki Y, Hirai H: Cloning of several species of MLL/MEN chimeric cDNAs in myeloid leukemia with t(11;19)(q23;p13.1) translocation. Blood 1995;85:2017-2024.
43. Mori N, Morosetti R, Spira S, Lee S, Ben-Yehuda D, Schiller G, Landolf R, Mizoguchi H, Koeffler HP: Chromosome band 1p36 contains a putative tumor suppressor gene important in the evolution of chronic myelogenous leukemia. Blood 1998;92:3405-3409.
44. Nakai H, Misawa S, Horiike S, Maekawa T, Kashima K, Ishizaki K: Hemizygous expression of the wild-type p53 allele may confer a selective growth advantage before complete inactivation of the p53 gene in the progression of chronic myelogenous leukaemia. Br J Haematol 1995; 90:147-155.
45. Oguchi K, Takagi M, Tsuchida R, Taya Y, Ito E, Isoyama K, Ishii E, Zannini L, Delia D, Mizutani S: Missense mutation and defective function of ATM in a childhood acute leukemia patient with MLL gene rearrangement. Blood 2003;101:3622-3627.
46. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP, Pelicci PG: PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000;406: 207-210.
47. Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON: BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 1991;66: 161-171.
48. Pierce A, Spooncer E, Wooley S, Dive C, Francis JM, Miyan J, Owen-Lynch PJ, Dexter TM, Whetton AD: BCR-ABL protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation. Oncogene 2000;19:5487-5497.
49. Poirel H, Rack K, Delabesse E, Radford-Weiss I, Troussard X, Debert C, Leboeuf D, Bastard C, Picard F, Veil-Buzyn A, Flandrin G, Bernard O, Macintyre E: Incidence and characterization of MLL gene (11q23) rearrangements in acute myeloid leukemia M1 and M5. Blood 1996;87:2496-2505.
50. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA: The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998;92:713-723.
51. Reich NC, Oren M, Levine AJ: Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol Cell Biol 1983;3:2143-2150.
52. Rowley JD, Testa JR: Chromosome abnormalities in malignant hematologic diseases. Adv Cancer Res 1982;36:103-148.
53. Secker-Walker LM, Moorman AV, Bain BJ, Mehta AB: Secondary acute leukemia and myelodys-plastic syndrome with 11q23 abnormalities. EU Concerted Action 11q23 Workshop. Leukemia 1998;12:840-844.
54. Simpson L, Parsons R: PTEN: Life as a tumor suppressor. Exp Cell Res 2001;264:29-41.
55. Sionov RV, Coen S, Goldberg Z, Berger M, Bercovich B, Ben-Neriah Y, Ciechanover A, Haupt Y: c-Abl regulates p53 levels under normal and stress conditions by preventing its nuclear export and ubiquitination. Mol Cell Biol 2001; 21:5869-5878.
56. Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Martinez R, Wasik MA, Calabretta B: Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase. Proc Natl Acad Sci USA 1996;93:13137-13142.
57. Stilgenbauer S, Dohner H: Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002; 347:452-453.
58. Thirman MJ, Gill HJ, Burnett RC, Mbangkollo D, McCabe NR, Kobayashi H, Zieminvan der Poel S, Kaneko Y, Morgan R, Sandberg AA et al: Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med 1993;329:909-914.
59. Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY, Taya Y, Prives C, Abraham RT: A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 1999;13:152-157.
60. Vousden KH, Lu X: Live or let die: The cell's response to p53. Nat Rev Cancer 2002;2:594-604.
61. Wahl GM, Carr AM: The evolution of diverse biological responses to DNA damage: Insights from yeast and p53. Nat Cell Biol 2001;3: E277-E286.
62. Ward Y, Gupta S, Jensen P, Wartmann M, Davis RJ, Kelly K: Control of MAP kinase activation by the mitogen-induced threonine/tyrosine phosphatase PAC1. Nature 1994;367:651-654.
63. Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T, Murate T, Saito H: The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 1994;84:3158-3165.
64. Yin Y, Liu YX, Jin YJ, Hall EJ, Barrett JC: PAC1 phosphatase is a transcription target of p53 in signalling apoptosis and growth suppression. Nature 2003;422:527-531.
65. Zhang Y, Xiong Y, Yarbrough WG: ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92:725-734.